These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 23847277)

  • 1. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
    Shabir S; Kaul B; Pachnio A; Banham GD; Smith H; Chand S; Jham S; Harper L; Ball S; Rahbar A; Söderberg-Nauclér C; Moss P; Borrows R
    J Am Soc Nephrol; 2013 Oct; 24(10):1698-708. PubMed ID: 23847277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMV-infected kidney grafts drive the expansion of blood-borne CMV-specific T cells restricted by shared class I HLA molecules via presentation on donor cells.
    Gatault P; Al-Hajj S; Noble J; Chevallier E; Piollet M; Forconi C; Gaudy-Graffin C; Thibault G; Miquelestorena-Standley E; Halimi JM; Büchler M; Lemoine R; Baron C
    Am J Transplant; 2018 Aug; 18(8):1904-1913. PubMed ID: 29377506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection.
    Christmas SE; Halliday D; Lawton N; Wang H; Abdalla I; Masters J; Hassan RL; Hart IJ; Khan N; Smith J; Hammad A; Bakran A
    Transpl Immunol; 2009 Dec; 22(1-2):99-104. PubMed ID: 19635559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Cytomegalovirus Infection Significantly Impacts Circulating T Cells in Kidney Transplant Recipients.
    Meijers RW; Litjens NH; Hesselink DA; Langerak AW; Baan CC; Betjes MG
    Am J Transplant; 2015 Dec; 15(12):3143-56. PubMed ID: 26211927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
    Ugarte-Torres A; Hoegh-Petersen M; Liu Y; Zhou F; Williamson TS; Quinlan D; Sy S; Roa L; Khan F; Fonseca K; Russell JA; Storek J
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant.
    López-Oliva MO; Martinez V; Buitrago A; Jiménez C; Rivas B; Escuin F; Santana MJ; Selgas R; Bellón T
    Transplantation; 2014 Apr; 97(8):839-45. PubMed ID: 24345896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
    Hughes D; Hafferty J; Fulton L; Friend P; Devaney A; Loke J; Welsh KI; Handa A; Klenerman P
    J Clin Virol; 2008 Feb; 41(2):92-5. PubMed ID: 18032098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
    Limaye AP; Green ML; Edmison BC; Stevens-Ayers T; Chatterton-Kirchmeier S; Geballe AP; Singh N; Boeckh M
    J Infect Dis; 2019 Jul; 220(5):752-760. PubMed ID: 31112280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control.
    Popescu I; Pipeling MR; Shah PD; Orens JB; McDyer JF
    J Immunol; 2014 Dec; 193(11):5709-5722. PubMed ID: 25339676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.
    Bruminhent J; Dajsakdipon T; Ingsathit A; Supaporn T; Prommool S; Watcharananan SP
    Transplant Proc; 2020 Apr; 52(3):829-835. PubMed ID: 32113693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation.
    Ganepola S; Gentilini C; Hilbers U; Lange T; Rieger K; Hofmann J; Maier M; Liebert UG; Niederwieser D; Engelmann E; Heilbronn R; Thiel E; Uharek L
    Bone Marrow Transplant; 2007 Mar; 39(5):293-9. PubMed ID: 17262060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.
    Zhou W; Longmate J; Lacey SF; Palmer JM; Gallez-Hawkins G; Thao L; Spielberger R; Nakamura R; Forman SJ; Zaia JA; Diamond DJ
    Blood; 2009 Jun; 113(25):6465-76. PubMed ID: 19369230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection.
    Eid AJ; Brown RA; Arthurs SK; Lahr BD; Eckel-Passow JE; Larson TS; Razonable RR
    Transpl Int; 2010 May; 23(5):506-13. PubMed ID: 19951371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.
    Egli A; Binet I; Binggeli S; Jäger C; Dumoulin A; Schaub S; Steiger J; Sester U; Sester M; Hirsch HH
    J Transl Med; 2008 Jun; 6():29. PubMed ID: 18541023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018; 50(1):124-129. PubMed ID: 29407294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis.
    Leeaphorn N; Garg N; Thamcharoen N; Khankin EV; Cardarelli F; Pavlakis M
    Am J Transplant; 2019 Feb; 19(2):573-584. PubMed ID: 30431703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.
    Gratama JW; van Esser JW; Lamers CH; Tournay C; Löwenberg B; Bolhuis RL; Cornelissen JJ
    Blood; 2001 Sep; 98(5):1358-64. PubMed ID: 11520783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection.
    Sester M; Sester U; Gärtner BC; Girndt M; Meyerhans A; Köhler H
    J Am Soc Nephrol; 2002 Oct; 13(10):2577-84. PubMed ID: 12239248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.